{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"4.2","upperLimit":"NA","value":"12.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"OS was defined as the time from start date of study treatment to date of death due to any cause. OS for participants not known to had died were censored on the date of last known alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 44 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 76 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 2A: PF-06863135 SC"}],"paramType":"MEDIAN","populationDescription":"mITT analysis set included all participants who have received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Time from start date of study treatment to date of death due to any cause or last-known-alive date, whichever occurred first (maximum up to 34.3 months)","title":"Part 2: OS","type":"SECONDARY","unitOfMeasure":"Months"}